Gene · 6752
Papers3,968
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
541 to 560 of 3,968
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Covalent Proteins as Targeted Radionuclide Therapies Enhance Antitumor Effects. | ACS Cent Sci | 2023 | 37396859 | PubTator, text mining | PubMed |
| First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs. | EJNMMI Radiopharm Chem | 2023 | 37389800 | PubTator, text mining | PubMed |
| Radiometal chelators for infection diagnostics. | Front Nucl Med | 2023 | 37388440 | PubTator, text mining | PubMed |
| Evaluation of [68Ga]-DOTATOC PET/MRI in Patients with Meningioma of the Subcranial and Intraorbital Space. | J Nucl Med | 2023 | 37385668 | PubTator, text mining | PubMed |
| Metamorphic gene regulation programs in Xenopus tropicalis tadpole brain. | PLoS One | 2023 | 37384728 | PubTator, text mining | PubMed |
| Hypercalcemia of malignancy caused by parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumors (PTHrP-PNETs): Case Report. | Front Oncol | 2023 | 37377908 | PubTator, text mining | PubMed |
| Clinical Advances and Perspectives in Targeted Radionuclide Therapy. | Pharmaceutics | 2023 | 37376181 | PubTator, text mining | PubMed |
| Radiochemical and Biological Evaluation of 3p-C-NETA-ePSMA-16, a Promising PSMA-Targeting Agent for Radiotheranostics. | Pharmaceuticals (Basel) | 2023 | 37375829 | PubTator, text mining | PubMed |
| Wall Tension and Tubular Resistance in Kidney Cystic Conditions. | Biomedicines | 2023 | 37371845 | PubTator, text mining | PubMed |
| Diffuse, Adult-Onset Nesidioblastosis/Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS): Review of the Literature of a Rare Cause of Hyperinsulinemic Hypoglycemia. | Biomedicines | 2023 | 37371827 | PubTator, text mining | PubMed |
| Recombinant α1-Microglobulin (rA1M) Protects against Hematopoietic and Renal Toxicity, Alone and in Combination with Amino Acids, in a 177Lu-DOTATATE Mouse Radiation Model. | Biomolecules | 2023 | 37371508 | PubTator, text mining | PubMed |
| Prognostic Models in Growth-Hormone- and Prolactin-Secreting Pituitary Neuroendocrine Tumors: A Systematic Review. | Diagnostics (Basel) | 2023 | 37371013 | PubTator, text mining | PubMed |
| The role of radiation therapy and systemic treatments in meningioma: The present and the future. | Cancer Med | 2023 | 37366279 | PubTator, text mining | PubMed |
| Primary intracranial sarcomas: a clinicopathological investigation. | Front Oncol | 2023 | 37361584 | PubTator, text mining | PubMed |
| Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience. | J Clin Endocrinol Metab | 2023 | 37357993 | PubTator, text mining | PubMed |
| DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy in vitro and in vivo. | Theranostics | 2023 | 37351169 | PubTator, text mining | PubMed |
| Voltage-Gated Sodium Channel NaV1.7 Inhibitors with Potent Anticancer Activities in Medullary Thyroid Cancer Cells. | Cancers (Basel) | 2023 | 37345144 | PubTator, text mining | PubMed |
| The Effects of Peptide Receptor Radionuclide Therapy on the Neoplastic and Normal Pituitary. | Cancers (Basel) | 2023 | 37345047 | PubTator, text mining | PubMed |
| Potential Role of Somatostatin Receptor Scintigraphy for In Vivo Imaging of Vulnerable Atherosclerotic Plaques and Its Association with Myocardial Perfusion Imaging Finding: A Preliminary Study. | Mol Imaging Radionucl Ther | 2023 | 37337773 | PubTator, text mining | PubMed |
| Case report of a patient with Erdheim-Chester disease presenting with neuro-endocrine symptoms and negative for BRAF mutation. | Medicine (Baltimore) | 2023 | 37335698 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6752/papers?page=28